Advertisement

AAPS PharmSciTech

, Volume 19, Issue 8, pp 3501–3511 | Cite as

Enhancement in the Transdermal and Localized Delivery of Honokiol Through Breast Tissue

  • Xinyi Gao
  • Meera Gujjar Patel
  • Pooja Bakshi
  • Dipali Sharma
  • Ajay K. Banga
Research Article Theme: Advances in Topical Delivery of Drugs
  • 68 Downloads
Part of the following topical collections:
  1. Theme: Advances in Topical Delivery of Drugs

Abstract

Honokiol is a natural phenolic anti-cancer compound isolated from an extract of seed cones from Magnolia grandiflora. This study investigated the transdermal delivery of honokiol using various enhancement methods and to explore the potential of honokiol to treat breast cancer directly via delivery through mammary papilla. Poration of dermatomed human skin with microneedles significantly increased the delivery of honokiol by nearly 3-fold (97.81 ± 18.96 μg/cm2) compared with passive delivery (32.56 ± 5.67 μg/cm2). Oleic acid was found to be the best chemical penetration enhancer, increasing the delivery almost 27-fold (868.06 ± 100.91 μg/cm2). Addition of oleic acid also resulted in better retention of drug in the porcine mammary papilla (965.41 ± 80.26 μg/cm2) compared with breast skin (294.16 ± 8.49 μg/cm2). Anti-cancer effect of honokiol was demonstrated with the decrease in the release of cytokine IL-6 and further suppression of Ki-67 proliferative protein. In addition, the topical honokiol formulation investigated was found to be safe and non-irritant. In summary, both microneedles and chemical enhancers can improve the absorption of honokiol through skin. Directly applying honokiol on mammary papilla is a potential administration route which can increase localized delivery into breast tissue.

KEY WORDS

honokiol breast cancer transdermal drug delivery microneedle chemical enhancer 

References

  1. 1.
    American Cancer Society. (2015) Cancer facts and figures 2015.Google Scholar
  2. 2.
    American Cancer Society. (2017) How common is breast cancer? [Internet]. Available at: https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html. Accessed 23 May 2017
  3. 3.
    Breastcancer.org (2017) U.S. breast cancer statics. [Internet]. Available at: http://www.breastcancer.org/symptoms/understand_bc/statistics. Accessed 23 May 2017
  4. 4.
    Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer. 2004;101:1947–57.CrossRefGoogle Scholar
  5. 5.
    Lee LM, Davison Z, Heard CM. In vitro delivery of anti-breast cancer agents directly via the mammary papillae (nipple). Int J Pharm. 2010;387(1–2):161–6.CrossRefGoogle Scholar
  6. 6.
    Lee Y-J, Lee YM, Lee C-K, Jung JK, Han SB, Hong JT. Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther. 2011;130(2):157–76.CrossRefGoogle Scholar
  7. 7.
    Watanabe K, Watanabe H, Goto Y, Yamaguchi M, Yamamoto N, Hagino K. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects. Planta Med. 1983;49:103–8.CrossRefGoogle Scholar
  8. 8.
    Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D. Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res. 2012;14:R35.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Shigemura K, Arbiser JL, Sun SY, Zayzafoon M, Johnstone PA, Fujisawa M, et al. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer. 2007;109:1279–89.CrossRefGoogle Scholar
  10. 10.
    Deng J, Qian Y, Geng L, Chen J, Wang X, Xie H, et al. Involvement of p38 mitogen-activated protein kinase pathway in honokiol-induced apoptosis in a human hepatoma cell line (hepG2). Liver Int. 2008;28:1458–64.CrossRefGoogle Scholar
  11. 11.
    Tsai TH, Chou CJ, Lee TF, Wang LCH, Chen CF. Pharmacokinetic and pharmacodynamic studies of magnolol after oral administration in rats. Pharmaceut Sci. 1996;2:191–3.Google Scholar
  12. 12.
    Bronaugh RL, Maibach HI. Percutaneous absorption. 4th ed. New York: Marcel Dekker; 2005.CrossRefGoogle Scholar
  13. 13.
    Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov. 2004;3:115–24.CrossRefGoogle Scholar
  14. 14.
    Banga AK. Transdermal and intradermal delivery of therapeutic agents: application of physical technologies. New York: CRC Press; 2011. p. 1–285.Google Scholar
  15. 15.
    Banga AK. Microporation applications for enhancing drug delivery. Expert Opin Drug Deliv. 2009;6:343–54.CrossRefGoogle Scholar
  16. 16.
    William AC, Barry BW. Penetration enhancer. Adv Drug Deliv. 2004;56:603–18.CrossRefGoogle Scholar
  17. 17.
    Barry BW. Lipid–protein-partititioning theory of skin penetration enhancement. J Control Release. 1991;15:237–48.CrossRefGoogle Scholar
  18. 18.
    Medical College of Georgia at Augusta University. (2017) Cancer therapy shows promise for psoriasis treatment. [Internet] ScienceDaily. Available at: www.sciencedaily.com/releases/2017/05/170531110758.htm. Accessed 31 May 2017
  19. 19.
    Dong HR, Liu XQ. HPLC analysis of magnolol and honokiol in magnoliae cortex after solvent sublation. Acta Chromatographica. 2008;20:147–56.CrossRefGoogle Scholar
  20. 20.
    MatTek Corporation (2017) In vitro EpiDerm TM skin irritation test (EPI-200-SIT) [Internet]. Available at: https://www.mattek.com/wp-content/uploads/Skin-Irritation-Test-Protocol.pdf. Accessed 12 April 2017
  21. 21.
    Rusby JE, Brachtel EF, Michaelson JS, Koerner FC, Smith BL. Breast duct anatomy in the human nipple: Threedimensional patterns and clinical implications. Breast Cancer Res Treat. 2007;106:171–9.CrossRefGoogle Scholar
  22. 22.
    Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, et al. Ductal access for prevention and therapy of mammary tumours. Cancer Res. 2006;66:638–45.CrossRefGoogle Scholar
  23. 23.
    Dave K, Averineni R, Sahdev P, Perumal O. Transpapillaery drug delivery to the breastPLoS One. 2014;9(12):e115712.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Li Z, Liu Y, Zhao X, Pan X, Yin R, Huang C, et al. Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells. Eur J Obstet Gynecol Reprod Biol. 2008;140:95–102.CrossRefGoogle Scholar
  25. 25.
    Garcia A, Zheng Y, Zhao C, Toschi A, Fan J, Shraibman N, et al. Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res. 2008;14:4267–74.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Zheng X, Wang X, Gou M, Zhang J, Men K, Chen L, et al. A novel transdermal honokiol formulation based on Pluronic F127 copolymer. Drug Deliv. 2010;17(3):138–44.CrossRefGoogle Scholar
  27. 27.
    Wang XH, Cai LL, Zhang XY, Deng LY, Zheng H, Deng CY, et al. Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol. Int J Pharm. 2011;410:169–74.CrossRefGoogle Scholar
  28. 28.
    Mortazavi SA, Aboofazeli R. An investigation into the effect of various penetration enhancers on percutaneous absorption of piroxicam. Iran J Pharm Res. 2003;2:135–40.Google Scholar
  29. 29.
    Wen Z, Fang L, He Z. Effect of chemical enhancers on percutaneous absorption of daphnetin in isopropyl myristate vehicle across rat skin in vitro. Drug Deliv. 2009;16(4):214–23.CrossRefGoogle Scholar
  30. 30.
    Vaddi HK, Wang LZ, Ho PC, Chan SY. Effect of some enhancers on the permeation of haloperidol through rat skin in vitro. Int J Pharm. 2001;212(2):247–55.CrossRefGoogle Scholar
  31. 31.
    Mura S, Manconi M, Sinico C, Valenti D, Fadda AM. Penetration enhancercontaining vesicles (PEVs) as carriers for cutaneous delivery of minoxidil. Int J Pharm. 2009;380(1–2):72–9.CrossRefGoogle Scholar
  32. 32.
    Sato A, Friend O, Nagai I. Effect and mode of action of aliphatic esters. Int J Pharm. 1988;43:31–40.CrossRefGoogle Scholar
  33. 33.
    Suomela S, Elomaa O, Skoog T, Ala-aho R, Jeskanen L, Pärssinen J, et al. CCHCR1 is up-regulated in skin cancer and associated with EGFR expression. PLoS One. 2009;4(6):e6030. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696036/. Accessed 11 Aug 2017CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Curr Mol Med. 2012 Dec;12(10):1244–52.CrossRefPubMedCentralGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Xinyi Gao
    • 1
  • Meera Gujjar Patel
    • 1
  • Pooja Bakshi
    • 1
  • Dipali Sharma
    • 2
  • Ajay K. Banga
    • 1
  1. 1.Center for Drug Delivery, Department of Pharmaceutical SciencesMercer UniversityAtlantaUSA
  2. 2.Department of OncologyJohns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA

Personalised recommendations